Skip to main content

Top Menu

  • Contact
  • Media
  • Careers
  • Staff
  • About Us
    • About CCTG
    • Committee Leadership
    • CCTG Scientific Leadership
    • CCTG Management
    • Careers at CCTG
    • CCTG policies
    • Contact us
  • Patients & Families
    • Patients & Families
    • Patient Representatives Committee
    • Patients as research partners
    • Resources for patients & families
    • Clinical trials - public
  • Disease Site Listings - Public

    Disease Site Listings - Public

    • All
    • Brain
    • Breast
    • Gastro-Intestinal
    • Genito-Urinary
    • Gynecologic
    • Head & Neck
    • Hematologic
    • IND
    • Lung
    • Melanoma
    • Multi-Site
    • Sarcoma
    • Symptom Control
  • Disease Site Listings - Members

    Disease Site Listings - Members

    • All
    • Brain
    • Breast
    • Gastro-Intestinal
    • Genito-Urinary
    • Gynecologic
    • Head & Neck
    • Hematologic
    • IND
    • Lung
    • Melanoma
    • Sarcoma
    • Symptom Control
    • Multi-Site
  • Clinical Trials
    • All Trials
    • Brain
    • Breast
    • Gastro-Intestinal
    • Genito-Urinary
    • Gynecologic
    • Head & Neck
    • Hematologic
    • IND
    • Lung
    • Melanoma
    • Sarcoma
    • Symptom Control
    • Multi-Site
    • Clinical trials - overview
    • All Trials
    • Brain
    • Breast
    • Gastro-Intestinal
    • Genito-Urinary
    • Gynecologic
    • Head & Neck
    • Hematologic
    • IND
    • Lung
    • Melanoma
    • Sarcoma
    • Symptom Control
    • Multi-Site
    • Publications

    Mobile CCTG Clinical Trials

    • Member Trial Pages
    • Public Trial Pages
    • Publications
    The Impact of the COVID-19 on Canadians Living with Cancer

    CCTG SC27 - The Impact of the COVID-19 on Canadians Living with Cancer

    CCTG has launched a patient-centred observational study: SC27 Living With Cancer in the Time of COVID-19: A Cohort Study of the Impact of the COVID-19 Pandemic on Cancer Patients During Treatment and Survivors. The aim of this study is to examine the emotional and physical consequences of living with cancer during this pandemic and the impact it may have on your quality of life and changes in your cancer care and follow-up.

    More >>

    Recently Activated Trials

    CLC3

    Venetoclax and Obinutuzumab vs DeLayed Therapy with VEnetoclax and Obinutuzumab in Asymptomatic High-Risk Patients with CLL/SLL (EVOLVE)

    More >>

    CLC3E

    Economic Analysis of Early vs Delayed Therapy in Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    More >>

    HD11

    Pembrolizumab and Brentuximab Vedotin vs GDP Followed by High Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma

    More >>

    MAC27

    COMPASSHER2 Residual Disease, A Double-Blinded, Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib

    More >>
  • Member Resources

    Member Links

    • Current Trial pages
    • Become a member
    • Toolbox
    • Funding information
    • Compliance and oversight
    • Audit, inspection & partner compliance
    • Generic protocols
    • Standing committees
    • Disease site & IND committees
    • Terms of reference
    • Group newsletter: CCTG Connection
    • Help & Support
    Practice changing OlympiA (CCTG MA36) trial results

    ASCO 2021 Plenary - Practice changing OlympiA (CCTG MA36) trial results

    Giving olaparib to patients with certain BRCA-mutated breast cancer for 1 year after they were treated with chemotherapy, surgery, or radiation significantly improved disease-free survival, according to the results that were presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting and were simultaneously published in the New England Journal of Medicine.

    More >>

    Planned Trials

    AL6

    MRD Driven Study of Venetoclax Plus Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML

    ALC7

    Master Screening and Reassessment Protocol (MSRP) for the NCI myeloMATCH clinical trials

    ALC8

    Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)

    ALC9

    Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)

    BLC5

    MAIN-CAV: Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab After First-Line Platinum Based Chemotherapy in Metastatic Urothelial Cancer

    More >>

    BR37

    Phase II Pre-operative Platform Trial in Surgically Resectable NSCLC

    Disease Site Committees

    • Brain
    • Breast
    • Gastro-Intestinal
    • Gynecologic
    • Genito-Urinary
    • Head & Neck Working Group
    • Hematologic
    • IND
    • IND Executive
    • Lung Disease
    • Melanoma
    • Sarcoma
  • Meetings & Education
    • Spring meeting of participants
      • CCTG recognition awards
      • Maria Ricci Memorial Lecture
    • New investigator cancer trials practicum
    • New investigator clinical trials course
    • Fellowships
    • The Frances A Shepherd Award
    • Conference presentations
  • Search

  • Donate
  • Toolbox
    • Applications
    • >>  EDC (Medidata Rave)
    • >>  iMedidata
    • >>  Mango
    • >>  Ripple
    • >>  Lettuce
    • >>  Sprout (ePRO)
    • Exposure Reporting
    • >>  CTEP website
    • >>  CTCAE v5.0 booklet
    • >>  CTCAE v4.0 booklet
    • >>  CTCAE v3.0 booklet
    • >>  CTEP-AERS reporting
    • >>  EDC SAE (paper report)
    • >>  Pregnancy reporting form
    • >>  Exposure reporting form
    • Support
    • >>  Passwords management
    • >>  CCTG contacts
    • >>  Support information
    • Tissue Bank
    • >>  Tissue Bank
    • >>  Inventory
    • >>  Tissue research
    • Reports
    • >>  Accrual utility (Monthly site accrual)
    • >>  Safety reports
    • >>  Papaya
    • >>  Ethics
    • >>  Trial closure
    • Data Management
    • >>  Baseline symptoms & adverse events
    • >>  Concomitant medications template
    • >>  SI conversion table
    • >>  iRECIST & RECIST guidelines
    • Training
    • >>  NIH ethics training
    • >>  Division 5 part C
    • >>  Good clinical practice
    • >>  Site training
    • >>  Supplementary training
  • Contact Us
  • Media
  • Staff

  Victoria Day Weekend Closure - May 20 (Queen’s U Holiday) & May 23 (Victoria Day)

CCTG Central Office will have coverage of critical activities only on Friday May 20 and will be closed Monday May 23 for Victoria Day.
Shipment of Specimens for Banking + Kit Supply - Richardson Laboratory will be closed both days, for shipment information: https://www.ctg.queensu.ca/bulletin/shipment-specimens-banking-kit-supply-holiday-closures
Regular business hours will resume on Tuesday May 24 at 8:30 am EST. All regular web-based applications will continue to be available.

  For the latest COVID-19 (Coronavirus) information: CCTG public updates | CCTG member information

Conference Presentations

Abstracts presented at the 2021 ASCO Annual (Virtual) Meeting
June 4-8, 2021
Abstracts presented at the 63rd ASH Annual Meeting
December 11-14, 2021
Abstracts presented at the Annual San Antonio Breast Cancer Symposium
Henry B. Gonzalez Convention Center
San Antonio, Texas
December 7-10, 2021

Landing Page - Meetings & Education

  • Spring meeting of participants
    • CCTG recognition awards
    • Maria Ricci Memorial Lecture
  • New investigator cancer trials practicum
  • New investigator clinical trials course
  • Fellowships
  • The Frances A Shepherd Award
  • Conference presentations
  • Partnerships 600+ trials in 40+ countries
  • IND Program 38+ years experience in 205+ drug trials
  • Tissue Bank 300,000+ samples from 120+ trials
  • Network 2100+ investigators at 85+ sites
  • Become a CCTG Investigator
Career Opportunities

Footer Menu

  • About us
  • Patients & Families
  • Clinical trials
  • Member resources
  • Meetings & Education
  • Publications
  • Toolbox
  • Contact us
  • Media centre
  • Staff
  • Careers

CANADIAN CANCER TRIALS GROUP

Cancer Research Institute
Queen's University

10 Stuart Street
Kingston, Ontario
Canada K7L 3N6

A NATIONAL PROGRAM OF THE:

 

OPERATIONS AND STATISTICAL CENTRE LOCATED AT:

PROUDLY AFFILIATED WITH:

As a national cooperative group, CCTG recognizes that Canada is situated on Indigenous lands, we acknowledge that the Operations and Statistics Centre, located at Queen’s University, is located on traditional Anishinaabe and Haudenosaunee Territory.
© Canadian Cancer Trials Group, 2021 | Terms & Conditions Facebook LinkedIn TwitterYouTube